Compare ELOG & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | BIVI |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 11.1M |
| IPO Year | N/A | 2013 |
| Metric | ELOG | BIVI |
|---|---|---|
| Price | $0.82 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 89.1K |
| Earning Date | 07-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.88 |
| 52 Week High | $3.07 | $9.09 |
| Indicator | ELOG | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 39.98 |
| Support Level | N/A | $1.16 |
| Resistance Level | $1.19 | $1.52 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 4.57 | 4.65 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.